Key Points
- Director David Epstein bought 5,000 AgomAb shares at an average price of $8.90, investing $44,500 and increasing his holdings by 50% to 15,000 shares.
- AgomAb shares opened at $9.08 and were down 1.5%, trading below their 50-day and 200-day moving averages. The stock has ranged from $7.97 to $17.82 over the past 52 weeks.
- Analyst sentiment remains broadly positive, with seven Buy ratings and one Hold, producing a “Moderate Buy” consensus and a $37.50 average price target, despite the company’s reported quarterly loss of $0.46 per share.
AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) Director David Epstein bought 5,000 shares of AgomAb Therapeutics stock in a transaction that occurred on Thursday, October 8th. The shares were acquired at an average cost of $8.90 per share, for a total transaction of $44,500.00. Following the acquisition, the director owned 15,000 shares in the company, valued at $133,500. The trade was a 50.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.
AgomAb Therapeutics Trading Down 1.5%
Shares of NASDAQ:AGMB opened at $9.08 on Friday. The company's fifty day moving average is $12.60 and its 200 day moving average is $11.93. AgomAb Therapeutics NV has a 52 week low of $7.97 and a 52 week high of $17.82.
AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that AgomAb Therapeutics NV will post -1.76 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on AGMB shares. Wall Street Zen lowered AgomAb Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 27th. HC Wainwright reiterated a "buy" rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. Piper Sandler began coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an "overweight" rating and a $60.00 price objective for the company. Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an "overweight" rating on the stock. Finally, B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a "buy" rating and a $34.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, AgomAb Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $37.50.
Check Out Our Latest Research Report on AGMB
AgomAb Therapeutics Company Profile
(
Get Free Report)
Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.
Agomab's lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn's disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
